Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Mon, 19.04.2021
MorphoSys AG
Press release
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
PLANEGG/MUNICH, Germany and WILMINGTON, Del. - April 19, 2021 - MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDA [ … ]
Mon, 25.01.2021
MorphoSys AG
Media ReleaseMorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
PLANEGG/MUNICH, Germany and SHANGHAI, China - January 25, 2021 - MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (NASDAQ: IMAB) today announced that the first patient has been d [ … ]
Tue, 12.01.2021
MorphoSys AG
Media ReleaseMorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
PLANEGG/MUNICH, Germany and MONTREAL, Canada - January 12, 2021 - MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ: INCY) today announced that Health Canada has accepted the New Drug Su [ … ]
Mon, 11.01.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 11, 2021
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul K [ … ]
Wed, 06.01.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 6, 2021
MorphoSys Appoints Sung Lee as Chief Financial Officer
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today the appointment of Sung Lee as Chief [ … ]
Tue, 05.01.2021
MorphoSys AG
Media ReleaseMorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
- The Swissmedic MAA seeks approval for tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
PLANEGG/MUNICH, Germany and MORGES, Switz [ … ]
Thu, 17.12.2020
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 17, 2020
MorphoSys AG: Corporate Calendar 2021
Dear Madam/Sir,
Please note MorphoSys's financial reporting dates 2021 as follows:
Publication of Interim Statement / Report
Conference Call
Year-End Results 2020
March 15, 2021 // 10 pm CET
(5 pm EDT; 9 pm GMT)
March 16, 2021 // [ … ]
Mon, 07.12.2020
MorphoSys AG
Media Release
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
- Preliminary safety and efficacy data from Phase 1b firstMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) presented today
- Also presented today: Long-term subgroup ana [ … ]
Wed, 02.12.2020
MorphoSys AG
Media ReleaseMorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
PLANEGG/MUNICH, Germany, December 2, 2020-MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research &am [ … ]
Tue, 01.12.2020
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 1, 2020
Thomas Biegi Joins MorphoSys as Head of Corporate Communications
MorphoSys (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that Thomas Biegi joins the company as Vice President, Head of Corporate Communications, effective December 1, 2020. In this newly crea [ … ]